BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
Find more results for BRIAN K. DAVIS
108.42
+1.35 (1.26%)
After Hours: 108.42 0.00 (0.00%)
Mar 2, 5:05PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 106.57 - 108.88
52 week 55.04 - 111.89
Open 107.00
Vol / Avg. 1.14M/1.34M
Mkt cap 16.66B
P/E     -
Div/yield     -
EPS -0.88
Shares 155.93M
Beta 0.93
Inst. own 98%
Apr 29, 2015
Q1 2015 Biomarin Pharmaceutical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 3, 2015
Biomarin Pharmaceutical Inc at Cowen Health Care Conference - 10:00AM EST - Add to calendar
Feb 25, 2015
Q4 2014 Biomarin Pharmaceutical Inc Earnings Call - Webcast
Feb 25, 2015
Q4 2014 Biomarin Pharmaceutical Inc Earnings Release
Feb 23, 2015
Biomarin Pharmaceutical Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
Feb 12, 2015
Biomarin Pharmaceutical Inc at Leerink Global Healthcare Conference
Jan 12, 2015
Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference - Webcast
Dec 10, 2014
Biomarin Pharmaceutical Inc Analyst and Investor Day
Dec 3, 2014
Biomarin Pharmaceutical Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 4.21% -32.15%
Operating margin 6.33% -30.81%
EBITD margin - -18.93%
Return on average assets 1.25% -9.25%
Return on average equity 2.01% -14.97%
Employees 1,341 -
CDP Score - -

Address

105 DIGITAL DRIVE
NOVATO, CA 94949
United States - Map
+1-415-5066700 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company�s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. The Company is conducting preclinical development of several other enzyme product candidates for genetic and other metabolic diseases, including BMN-190 for the treatment of late infantile neuronal ceroid lipofuscinosis (LINCL), a form of Batten disease.

Officers and directors

Pierre Lapalme Director
Age: 73
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel K. Spiegelman Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 59
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Executive Vice President and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
G. Eric Davis Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Richard J. Ranieri Senior Vice President - Human Resources and Corporate Affairs
Age: 60
Bio & Compensation  - Reuters
Brian R. Mueller Group Vice President, Corporate Controller
Age: 40
Bio & Compensation  - Reuters
Dennis J. Slamon M.D., Ph.D. Director
Age: 65
Bio & Compensation  - Reuters